Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bone BiologicsBBLG -0.93%30 Current Ratio is 16.11 as of Mar. 2026, which is 343% above its 10-year median of 3.64. GuruFocus rates BBLG with a GF Score™ of 30/100. Among 1,411 Biotechnology companies, Bone Biologics ranks better than 88.16% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Bone Biologics's current ratio for the quarter that ended in Mar. 2026 was 16.11.
Bone Biologics has a current ratio of 16.11. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Bone Biologics's Current Ratio or its related term are showing as below:
BBLG'
s Current Ratio Range Over the Past 10 Years
Min: 0.01 Med: 3.64 Max: 110.8
Current: 16.11
During the past 12 years, Bone Biologics's highest Current Ratio was 110.80. The lowest was 0.01. And the median was 3.64.
BBLG's Current Ratio is ranked better than 88.16% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs BBLG: 16.11
Bone Biologics (NAS:BBLG) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Bone Biologics Current Ratio Related Terms
Bone Biologics Current Ratio Historical Data
* Premium members only.
The historical data trend for Bone Biologics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BBLG vs VRAX, PKTX, OGEN: Current Ratio Comparison
For the Biotechnology subindustry, Bone Biologics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bone Biologics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bone Biologics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Bone Biologics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bone Biologics (BBLG) has a Current Ratio of 16.11 as of Mar. 2026. This is 343% above median its historical median of 3.64. Over the past decade, Bone Biologics' Current Ratio has ranged from 0.01 to 110.80. According to the industry distribution chart, Bone Biologics ranks #167 out of 1411 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Bone Biologics' Current Ratio too high?
Bone Biologics' current Current Ratio of 16.11 is 343% above median its 10-year median of 3.64. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 110.80. The Biotechnology industry median Current Ratio is 3.88. Bone Biologics' value of 16.11 is 315.2% above this industry median. Based on the distribution chart, Bone Biologics ranks #167 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bone Biologics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Bone Biologics' Current Ratio compare to VRAX and PKTX?
According to the Biotechnology industry distribution chart, Bone Biologics ranks #167 out of 1411 companies for Current Ratio. This places Bone Biologics in the top 12% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. Bone Biologics' value of 16.11 is 315.2% above this benchmark. Historically, Bone Biologics' own Current Ratio has ranged from 0.01 to 110.80 over the past decade. While the company's 10-year median is 3.64 vs. the industry median of 3.88, Bone Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bone Biologics's current Current Ratio of 16.11 is 315.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bone Biologics's current Current Ratio is 16.11, which is 343% above median its own 10-year median of 3.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bone Biologics stock overvalued right now?
Bone Biologics (BBLG) has a current Current Ratio of 16.11. The current Current Ratio is 16.11, which is 343% above median its 10-year median of 3.64 and 315.2% above the Biotechnology industry median of 3.88. Bone Biologics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Bone Biologics (BBLG), the current Current Ratio is 16.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
30GF Score
Get the complete analysis for BBLG
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBLG has been successfully added to your 
